New CERE-120 to begin recruiting
 

Ceregene Initiates A New Controlled Phase 2b Trial Of CERE-120 For Parkinson’s Disease

SAN DIEGO, Oct. 19 /PRNewswire
http://www.dailymarkets.com/stock/20...nsons-disease/

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson’s disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons.

Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).


The first Phase II trial began recruiting in 2007. Per Ceregene, that trial did not meet the anticipated endpoints.
So, this "new" Phase I/II trial is now recruiting; putamen only. The brain target in the first trial is not the same as the brain target in this new trial; both substantia nigra and putamen.

Ceregene raises $11.5 million in venture funding round
 

Ceregene raises $11.5 million in venture funding round

San Diego : CA : USA | Nov 12, 2010
Source: San Diego Union-Tribune

Ceregene, a privately held San Diego drug developer, said it raised $11.5 million from four venture capital firms. Parkinson's disease that is surgically implanted in the brain. Ceregene recently started recruiting 52 patients to participate in the study nearly two years after an initial phase...

FULL ARTICLE AT San Diego Union-Tribune

wrong place